Vertex Pharmaceuticals Profit Margin

Vertex Pharmaceuticals's profit margin stands at 30.7% as of September 2026. That compares with 31.35% in the prior-year period — down 2.1% year over year. That is above the Healthcare sector average of 9.48%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Vertex Pharmaceuticals reported 30.7% in profit margin versus 31.35% a year earlier — a 2.1% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

Vertex Pharmaceuticals sits higher the Healthcare benchmark (9.48%) with a profit margin of 30.7%. That is roughly 223.8% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A profit margin of 30.7% for Vertex Pharmaceuticals means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how Vertex Pharmaceuticals's profit margin evolved across reporting periods, while the comparison chart places VRTX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.